Read about the move to scale use of AI across all FDA centers by the end of June and learn more about future plans to expand ...

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

The FDA  plans to launch generative AI across all of its centers by June 30. The agency has also appointed its first chief AI ...

The FDA is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, part of a bid to get faster and leaner in evaluating drugs, foods, medical devices and diagnostic ...

U.S. and China to pause most tariffs for 90 days, slash reciprocal rates. Amazon-backed Scale AI sets sights on Saudi ...

VUNO Med®-DeepCARS® (DeepCARS) is an AI-powered medical device designed to monitor the risk of in-hospital cardiac arrest within the next 24 hours. It analyzes patients' vital signs-including blood ...

Looking Ahead The FDA’s full-scale adoption of AI technology represents a leap forward in regulatory oversight. By ...

The success of AI in healthcare is influenced more by human factors and organizational readiness than by the technology ...

The FDA expects to fully integrate its AI approach by June 30, though its different centers have been instructed to start the ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...